mitotane has been researched along with Local Neoplasm Recurrence in 54 studies
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy." | 8.98 | Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( Liang, J; Liu, Z; Lu, Y; Tang, Y; Zhu, Y; Zou, Z, 2018) |
| "Description of novel findings about the mechanism of action of mitotane and its activity as an adjunctive postoperative measure, or for treatment of advanced adrenocortical carcinoma." | 8.90 | Practical treatment using mitotane for adrenocortical carcinoma. ( Allasino, B; De Francia, S; Terzolo, M; Zaggia, B, 2014) |
| "Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent." | 7.96 | Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. ( Altieri, B; Basile, V; Berruti, A; Canu, L; Della Casa, S; Fassnacht, M; Fragoso, MCBV; Kircher, S; Kroiss, M; Lacombe, AMF; Landwehr, LS; Megerle, F; Paiva, I; Ronchi, CL; Sbiera, S; Schreiner, J; Terzolo, M; Volante, M; Weigand, I; Zerbini, MCN, 2020) |
| "In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC)." | 7.85 | Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. ( Arvat, E; Berruti, A; Boscaro, M; Claps, M; Daffara, F; Fassnacht, M; Grisanti, S; Hahner, S; Loli, P; Mannelli, M; Porpiglia, F; Pulzer, A; Terzolo, M; Tiberio, G; Volante, M; Zaggia, B, 2017) |
| "Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC)." | 7.79 | Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. ( Al Ghuzlan, A; Allolio, B; Ardito, A; Baudin, AE; Berruti, A; Daffara, F; De Francia, S; deVries, JH; Fassnacht, M; Feelders, RA; Haak, HR; Kroiss, M; Leboulleux, S; Perotti, P; Terzolo, M; Volante, M; Zaggia, B, 2013) |
| "Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma." | 7.74 | Adjuvant mitotane treatment for adrenocortical carcinoma. ( Allolio, B; Ambrosi, B; Angeli, A; Arvat, E; Berruti, A; Bollito, E; Bruzzi, P; Buci, L; Conton, PA; Daffara, F; Dogliotti, L; Fassnacht, M; Grossrubatscher, E; Hahner, S; Koschker, AC; Loli, P; Lombardi, G; Mannelli, M; Mantero, F; Papotti, M; Reimondo, G; Rossetto, R; Saeger, W; Sperone, P; Tauchmanova, L; Terzolo, M, 2007) |
| " IMC-A12 was dosed at 10 mg/kg intravenously every 2 weeks." | 6.79 | The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. ( Agamah, E; Else, T; Hammer, GD; Hasseltine, EA; Hesseltine, EA; Lerario, AM; Ramm, CA; Rao, K; Shah, MH; Stadler, WM; Worden, FP, 2014) |
| "Mitotane was administered to 2 patients as an adjuvant therapy and to 8 patients for systemic control." | 5.62 | Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. ( Fukuda, N; Hayashi, N; Inamura, K; Komai, Y; Nakano, K; Numao, N; Ohmoto, A; Ono, M; Sato, Y; Shigematsu, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yonese, J; Yuasa, T; Yunokawa, M, 2021) |
| "Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III), hormone secretion (yes vs no) and Ki67 index." | 5.51 | Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Saba, L; Terzolo, M; Veltri, A; Volante, M, 2019) |
| "By treatment with Mitotane in a dose aiming at completely destroying the adrenal cortex, a complete disappearance of the tumor as well as a dramatic reduction of the size of the metastases could be achieved." | 5.30 | [Mitotane treatment in a dog with a recurring adrenocortical carcinoma--a case report]. ( Flückiger, M; Gardelle, O; Keiser, M; Reusch, C, 1999) |
| "Treatment with mitotane was started shortly after surgical removal of the tumor (three patients) or the tumor and multiple lung metastasis (one patient)." | 5.30 | Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? ( Arad, E; Best, LA; Dickstein, G; Nativ, O; Shechner, C, 1998) |
| "A 58-year-old man had adrenocortical carcinoma in the right adrenal gland." | 5.30 | Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999) |
| "Adrenal cortical carcinoma is a rare tumour with a poor prognosis." | 5.28 | Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. ( Cheah, JS; Chong, PY; Lim, MC; Tan, YO, 1990) |
| "Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy for patients with early-stage adrenocortical carcinoma (ACC)." | 5.22 | Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? ( Abate, A; Berruti, A; Cosentini, D; Cremaschi, V; Grisanti, S; Laganà, M; Rossini, E; Sigala, S; Tamburello, M; Turla, A, 2022) |
| "A recent nonrandomized interinstitutional study reported that adjuvant mitotane following surgery for adrenocortical carcinoma (ACC) was associated with decreased recurrence." | 5.14 | Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. ( Callender, GG; Evans, DB; Grubbs, EG; Lee, JE; Perrier, ND; Phan, AT; Xing, Y, 2010) |
| "The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy." | 4.98 | Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( Liang, J; Liu, Z; Lu, Y; Tang, Y; Zhu, Y; Zou, Z, 2018) |
| "Description of novel findings about the mechanism of action of mitotane and its activity as an adjunctive postoperative measure, or for treatment of advanced adrenocortical carcinoma." | 4.90 | Practical treatment using mitotane for adrenocortical carcinoma. ( Allasino, B; De Francia, S; Terzolo, M; Zaggia, B, 2014) |
| "Mitotane has been used for 50 years as the first-line drug in the treatment of disseminated adrenocortical carcinoma." | 4.86 | [Mitotane in the treatment of adrenal carcinoma]. ( Sane, T, 2010) |
| "A retrospective analysis showing that adjuvant mitotane may prolong recurrence-free survival in a large cohort of patients with radically resected adrenocortical carcinoma has recently been published." | 4.84 | Adjunctive treatment of adrenocortical carcinoma. ( Berruti, A; Terzolo, M, 2008) |
| "Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent." | 3.96 | Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. ( Altieri, B; Basile, V; Berruti, A; Canu, L; Della Casa, S; Fassnacht, M; Fragoso, MCBV; Kircher, S; Kroiss, M; Lacombe, AMF; Landwehr, LS; Megerle, F; Paiva, I; Ronchi, CL; Sbiera, S; Schreiner, J; Terzolo, M; Volante, M; Weigand, I; Zerbini, MCN, 2020) |
| "In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC)." | 3.85 | Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. ( Arvat, E; Berruti, A; Boscaro, M; Claps, M; Daffara, F; Fassnacht, M; Grisanti, S; Hahner, S; Loli, P; Mannelli, M; Porpiglia, F; Pulzer, A; Terzolo, M; Tiberio, G; Volante, M; Zaggia, B, 2017) |
| "Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC)." | 3.79 | Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. ( Al Ghuzlan, A; Allolio, B; Ardito, A; Baudin, AE; Berruti, A; Daffara, F; De Francia, S; deVries, JH; Fassnacht, M; Feelders, RA; Haak, HR; Kroiss, M; Leboulleux, S; Perotti, P; Terzolo, M; Volante, M; Zaggia, B, 2013) |
| "Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma." | 3.74 | Adjuvant mitotane treatment for adrenocortical carcinoma. ( Allolio, B; Ambrosi, B; Angeli, A; Arvat, E; Berruti, A; Bollito, E; Bruzzi, P; Buci, L; Conton, PA; Daffara, F; Dogliotti, L; Fassnacht, M; Grossrubatscher, E; Hahner, S; Koschker, AC; Loli, P; Lombardi, G; Mannelli, M; Mantero, F; Papotti, M; Reimondo, G; Rossetto, R; Saeger, W; Sperone, P; Tauchmanova, L; Terzolo, M, 2007) |
| " IMC-A12 was dosed at 10 mg/kg intravenously every 2 weeks." | 2.79 | The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. ( Agamah, E; Else, T; Hammer, GD; Hasseltine, EA; Hesseltine, EA; Lerario, AM; Ramm, CA; Rao, K; Shah, MH; Stadler, WM; Worden, FP, 2014) |
| " The therapeutic range is close and therefore dosage is difficult, mainly based on clinical signs." | 2.70 | [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels]. ( Heilmann, P; Nawroth, PP; Wagner, P; Ziegler, R, 2001) |
| "Even after complete surgery, recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists as to whether all patients benefit from this therapy." | 2.49 | Update in adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M, 2013) |
| "The management of adrenocortical carcinoma (ACC) recurrences remains controversial, and we present herein our experience with postoperative ACC recurrences." | 1.91 | The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients. ( Basile, V; Berchialla, P; Borin, C; Calabrese, A; Fiori, C; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Terzolo, M; Veltri, A; Volante, M, 2023) |
| "The prognosis of adrenocortical carcinoma (ACC) is poor but highly variable." | 1.91 | Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience. ( Huang, CJ; Lin, LY; Ng, XN; Pan, LH; Yen, CC, 2023) |
| "Mitotane was administered to 2 patients as an adjuvant therapy and to 8 patients for systemic control." | 1.62 | Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. ( Fukuda, N; Hayashi, N; Inamura, K; Komai, Y; Nakano, K; Numao, N; Ohmoto, A; Ono, M; Sato, Y; Shigematsu, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yonese, J; Yuasa, T; Yunokawa, M, 2021) |
| "Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III), hormone secretion (yes vs no) and Ki67 index." | 1.51 | Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Saba, L; Terzolo, M; Veltri, A; Volante, M, 2019) |
| "Adrenocortical carcinoma is a rare and aggressive malignancy with an incidence of 0." | 1.51 | A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore. ( Ali, A; Anwar, AW; Bakar, MA; Khan, MA; Khan, MS; Tariq, I, 2019) |
| "Mitotane was administered in 12 (71 %) patients with stage III-IV ACCs with a 5-year survival rate 25 % compared to 20 % in patients who did not receive Mitotane." | 1.42 | Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm. ( Abdel-Aziz, TE; Mihai, R; Rajeev, P; Sadler, G; Weaver, A, 2015) |
| "Adrenocortical carcinoma is a rare malignant endocrine neoplasia." | 1.40 | Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. ( Else, T; Hammer, GD; Jolly, S; Miller, BS; Sabolch, A; Williams, AR, 2014) |
| "Median survival in stage II adrenocortical carcinoma (ACC) differs widely in published series ranging between 23 and more than 60 months." | 1.36 | Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. ( Agha, A; Allolio, B; Beuschlein, F; Fassnacht, M; Fenske, W; Führer, D; Hahner, S; Johanssen, S; Jurowich, C; Petersenn, S; Quinkler, M; Spahn, M; Weismann, D, 2010) |
| "In suspected nonmetastatic adrenocortical carcinoma (ACC) a careful preoperative diagnostic work up is needed including comprehensive endocrine analysis as recommended by the European Network for the Study of Adrenal Tumors (http://www." | 1.36 | What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? ( Allolio, B; Fassnacht, M, 2010) |
| "Establishing a database for adrenocortical carcinomas in the UK would contribute to our understanding of the management of this disease." | 1.35 | How is adrenocortical cancer being managed in the UK? ( Aspinall, SR; Bliss, RD; Harrison, BJ; Imisairi, AH; Lennard, TW; Scott-Coombes, D, 2009) |
| "Mitotane was given to 67 evaluable patients with recurrent ACC." | 1.34 | Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. ( Evans, DB; Gonzalez, RJ; Lee, JE; Ng, C; Perrier, ND; Phan, AT; Tamm, EP; Vassilopoulou-Sellin, R, 2007) |
| "Local tumor recurrence is common in adrenocortical carcinoma (ACC) and is the most frequent cause for reoperation." | 1.33 | Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Flentje, M; Hahner, S; Kenn, W; Koschker, AC; Polat, B, 2006) |
| "By treatment with Mitotane in a dose aiming at completely destroying the adrenal cortex, a complete disappearance of the tumor as well as a dramatic reduction of the size of the metastases could be achieved." | 1.30 | [Mitotane treatment in a dog with a recurring adrenocortical carcinoma--a case report]. ( Flückiger, M; Gardelle, O; Keiser, M; Reusch, C, 1999) |
| "A 58-year-old man had adrenocortical carcinoma in the right adrenal gland." | 1.30 | Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999) |
| "Treatment with mitotane was started shortly after surgical removal of the tumor (three patients) or the tumor and multiple lung metastasis (one patient)." | 1.30 | Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? ( Arad, E; Best, LA; Dickstein, G; Nativ, O; Shechner, C, 1998) |
| "Adrenocortical carcinoma is a rare and aggressive disease with a poor prognosis." | 1.29 | Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. ( Guinee, VF; Hess, KR; Klein, MJ; Samaan, NA; Schultz, PN; Taylor, SH; Vassilopoulou-Sellin, R, 1993) |
| "Mitotane therapy was ineffective at controlling tumor growth." | 1.28 | Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. ( Jensen, JC; Norton, JA; Pass, HI; Sindelar, WF, 1991) |
| "Adrenocortical carcinoma is a rare disease which is primarily approached surgically." | 1.28 | Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. ( Brady, LW; Markoe, AM; Micaily, B; Serber, W, 1991) |
| "Adrenal cortical carcinoma is a rare tumour with a poor prognosis." | 1.28 | Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. ( Cheah, JS; Chong, PY; Lim, MC; Tan, YO, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (7.41) | 18.7374 |
| 1990's | 12 (22.22) | 18.2507 |
| 2000's | 11 (20.37) | 29.6817 |
| 2010's | 21 (38.89) | 24.3611 |
| 2020's | 6 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Terzolo, M | 9 |
| Fassnacht, M | 11 |
| Cremaschi, V | 1 |
| Abate, A | 1 |
| Cosentini, D | 1 |
| Grisanti, S | 2 |
| Rossini, E | 1 |
| Laganà, M | 1 |
| Tamburello, M | 1 |
| Turla, A | 1 |
| Sigala, S | 1 |
| Berruti, A | 7 |
| Calabrese, A | 2 |
| Puglisi, S | 2 |
| Borin, C | 1 |
| Basile, V | 3 |
| Perotti, P | 3 |
| Pia, A | 2 |
| Berchialla, P | 2 |
| Volante, M | 5 |
| Fiori, C | 1 |
| Porpiglia, F | 3 |
| Veltri, A | 2 |
| Reimondo, G | 3 |
| Pan, LH | 1 |
| Yen, CC | 1 |
| Huang, CJ | 1 |
| Ng, XN | 1 |
| Lin, LY | 1 |
| Weigand, I | 1 |
| Altieri, B | 1 |
| Lacombe, AMF | 1 |
| Kircher, S | 1 |
| Landwehr, LS | 1 |
| Schreiner, J | 1 |
| Zerbini, MCN | 1 |
| Ronchi, CL | 1 |
| Megerle, F | 1 |
| Canu, L | 1 |
| Paiva, I | 2 |
| Della Casa, S | 1 |
| Sbiera, S | 1 |
| Fragoso, MCBV | 1 |
| Kroiss, M | 4 |
| Ohmoto, A | 1 |
| Shigematsu, Y | 1 |
| Fukuda, N | 1 |
| Wang, X | 1 |
| Urasaki, T | 1 |
| Hayashi, N | 1 |
| Sato, Y | 1 |
| Nakano, K | 1 |
| Yunokawa, M | 1 |
| Ono, M | 1 |
| Komai, Y | 1 |
| Numao, N | 1 |
| Yuasa, T | 1 |
| Yonese, J | 1 |
| Tomomatsu, J | 1 |
| Inamura, K | 1 |
| Takahashi, S | 1 |
| Pulzer, A | 2 |
| Claps, M | 1 |
| Daffara, F | 3 |
| Loli, P | 2 |
| Mannelli, M | 2 |
| Boscaro, M | 1 |
| Arvat, E | 2 |
| Tiberio, G | 1 |
| Hahner, S | 4 |
| Zaggia, B | 3 |
| Shuayb, M | 1 |
| Das, A | 1 |
| Uddin, MN | 1 |
| Tang, Y | 1 |
| Liu, Z | 1 |
| Zou, Z | 1 |
| Liang, J | 1 |
| Lu, Y | 1 |
| Zhu, Y | 1 |
| Saba, L | 1 |
| Khan, MS | 1 |
| Ali, A | 1 |
| Tariq, I | 1 |
| Khan, MA | 1 |
| Bakar, MA | 1 |
| Anwar, AW | 1 |
| Freire, DS | 1 |
| Siqueira, SA | 1 |
| Zerbini, MC | 1 |
| Wajchenberg, BL | 1 |
| Corrêa-Giannella, ML | 1 |
| Lucon, AM | 1 |
| Pereira, MA | 1 |
| Baudin, AE | 1 |
| Ardito, A | 1 |
| Leboulleux, S | 1 |
| Feelders, RA | 1 |
| deVries, JH | 1 |
| De Francia, S | 2 |
| Haak, HR | 1 |
| Allolio, B | 7 |
| Al Ghuzlan, A | 1 |
| Else, T | 2 |
| Williams, AR | 1 |
| Sabolch, A | 1 |
| Jolly, S | 1 |
| Miller, BS | 1 |
| Hammer, GD | 2 |
| Allasino, B | 1 |
| Lerario, AM | 1 |
| Worden, FP | 1 |
| Ramm, CA | 1 |
| Hesseltine, EA | 1 |
| Hasseltine, EA | 1 |
| Stadler, WM | 1 |
| Shah, MH | 1 |
| Agamah, E | 1 |
| Rao, K | 1 |
| Abdel-Aziz, TE | 1 |
| Rajeev, P | 1 |
| Sadler, G | 1 |
| Weaver, A | 1 |
| Mihai, R | 2 |
| Ranvier, GG | 1 |
| Inabnet, WB | 1 |
| Baur, J | 1 |
| Schedelbeck, U | 1 |
| Bluemel, C | 1 |
| Wild, V | 1 |
| Steger, U | 1 |
| Guelho, D | 1 |
| Vieira, A | 1 |
| Carrilho, F | 1 |
| Aspinall, SR | 1 |
| Imisairi, AH | 1 |
| Bliss, RD | 1 |
| Scott-Coombes, D | 1 |
| Harrison, BJ | 1 |
| Lennard, TW | 1 |
| Grubbs, EG | 1 |
| Callender, GG | 1 |
| Xing, Y | 1 |
| Perrier, ND | 2 |
| Evans, DB | 3 |
| Phan, AT | 2 |
| Lee, JE | 3 |
| Johanssen, S | 1 |
| Fenske, W | 2 |
| Weismann, D | 1 |
| Agha, A | 1 |
| Beuschlein, F | 1 |
| Führer, D | 1 |
| Jurowich, C | 2 |
| Quinkler, M | 1 |
| Petersenn, S | 1 |
| Spahn, M | 1 |
| Sane, T | 1 |
| Reibetanz, J | 1 |
| Deutschbein, T | 1 |
| Gasser, M | 1 |
| Germer, CT | 1 |
| Kvacheniuk, AN | 1 |
| Brauckhoff, M | 1 |
| Dralle, H | 2 |
| Martins, AC | 1 |
| Cologna, AJ | 1 |
| Tucci, S | 1 |
| Suaid, HJ | 1 |
| Falconi, RA | 1 |
| Polat, B | 1 |
| Koschker, AC | 2 |
| Kenn, W | 1 |
| Flentje, M | 1 |
| Angeli, A | 1 |
| Tauchmanova, L | 1 |
| Conton, PA | 1 |
| Rossetto, R | 1 |
| Buci, L | 1 |
| Sperone, P | 1 |
| Grossrubatscher, E | 1 |
| Bollito, E | 1 |
| Papotti, M | 1 |
| Saeger, W | 1 |
| Ambrosi, B | 1 |
| Lombardi, G | 1 |
| Bruzzi, P | 1 |
| Mantero, F | 1 |
| Dogliotti, L | 1 |
| Carmona-Bayonas, A | 1 |
| Soler, IO | 1 |
| Gómez, FI | 1 |
| Billalabeitia, EG | 1 |
| Saura, HP | 1 |
| Tafalla, MS | 1 |
| Díaz, MP | 1 |
| Machens, A | 1 |
| Gonzalez, RJ | 1 |
| Tamm, EP | 1 |
| Ng, C | 1 |
| Vassilopoulou-Sellin, R | 3 |
| Schteingart, DE | 1 |
| Motazedi, A | 1 |
| Noonan, RA | 1 |
| Thompson, NW | 1 |
| Lobel, H | 1 |
| Rudnicki, K | 1 |
| Zahavi, I | 1 |
| Berger, DH | 1 |
| el-Naggar, AK | 1 |
| Hickey, RC | 1 |
| Gagel, RF | 1 |
| Burgess, MA | 1 |
| Favia, G | 1 |
| Lumachi, F | 1 |
| Carraro, P | 1 |
| D'Amico, DF | 1 |
| Guinee, VF | 1 |
| Klein, MJ | 1 |
| Taylor, SH | 1 |
| Hess, KR | 1 |
| Schultz, PN | 1 |
| Samaan, NA | 1 |
| Kasperlik-Załuska, AA | 1 |
| Migdalska, BM | 1 |
| Makowska, AM | 1 |
| Dickstein, G | 1 |
| Shechner, C | 1 |
| Arad, E | 1 |
| Best, LA | 1 |
| Nativ, O | 1 |
| Keiser, M | 1 |
| Flückiger, M | 1 |
| Gardelle, O | 1 |
| Reusch, C | 1 |
| Seki, M | 1 |
| Nomura, K | 1 |
| Hirohara, D | 1 |
| Kanazawa, M | 1 |
| Sawada, T | 1 |
| Takasaki, K | 1 |
| Demura, H | 1 |
| Heilmann, P | 1 |
| Wagner, P | 1 |
| Nawroth, PP | 1 |
| Ziegler, R | 1 |
| Pommier, RF | 1 |
| Brennan, MF | 1 |
| van Aalderen, W | 1 |
| van Seters, AP | 1 |
| Backer, ET | 1 |
| Chang, PC | 1 |
| van Krieken, JH | 1 |
| Moolenaar, AJ | 1 |
| Jensen, JC | 1 |
| Pass, HI | 1 |
| Sindelar, WF | 1 |
| Norton, JA | 1 |
| Markoe, AM | 1 |
| Serber, W | 1 |
| Micaily, B | 1 |
| Brady, LW | 1 |
| Lim, MC | 1 |
| Tan, YO | 1 |
| Chong, PY | 1 |
| Cheah, JS | 1 |
| Donckier, JE | 1 |
| Michel, LA | 1 |
| Berbinschi, A | 1 |
| De Coster, PM | 1 |
| De Plaen, JF | 1 |
| Ketelslegers, JM | 1 |
| Buysschaert, M | 1 |
| Levy, JM | 1 |
| Lutz, P | 1 |
| Wagner, C | 1 |
| Sauer, P | 1 |
| Seiller, F | 1 |
| Fischbach, M | 1 |
| Segura, N | 1 |
| Sauvage, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence[NCT03723941] | Phase 3 | 240 participants (Anticipated) | Interventional | 2018-07-01 | Recruiting | ||
| Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry[NCT00453674] | 1,000 participants (Anticipated) | Observational | 2003-01-31 | Recruiting | |||
| Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence[NCT00777244] | Phase 3 | 200 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy[NCT00786110] | Phase 2 | 30 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma[NCT02015026] | 67 participants (Actual) | Observational | 2013-12-13 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for mitotane and Local Neoplasm Recurrence
| Article | Year |
|---|---|
ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Humans; | 2022 |
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined C | 2022 |
Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, | 2018 |
Update in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, | 2013 |
Practical treatment using mitotane for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2014 |
Diagnosis, treatment and outcome of adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hor | 2015 |
Surgical management of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2015 |
[Mitotane in the treatment of adrenal carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan | 2010 |
[German adrenocortical carcinoma registry. Surgical therapy results and follow-up treatment].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Aftercare; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2012 |
[Recurrent operations on the adrenal glands].
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Anti | 2005 |
Adjunctive treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemother | 2008 |
Adrenocortical carcinoma. Our experience.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adult; Aged; Antineoplastic Combined Chemothera | 1995 |
3 trials available for mitotane and Local Neoplasm Recurrence
| Article | Year |
|---|---|
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, | 2014 |
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, | 2010 |
[Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe | 2001 |
39 other studies available for mitotane and Local Neoplasm Recurrence
| Article | Year |
|---|---|
The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan | 2023 |
Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Mitotane; Neoplasm Recurrence, L | 2023 |
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineopla | 2020 |
Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Japan; | 2021 |
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 | 2017 |
Long-term survival in recurrent adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Adult; Antineoplastic Combined C | 2019 |
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, | 2019 |
A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcino | 2019 |
Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence.
Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineo | 2013 |
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineo | 2013 |
Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 | 2014 |
Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Antineoplas | 2015 |
A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2015 |
Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Chemothe | 2016 |
How is adrenocortical cancer being managed in the UK?
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2009 |
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti | 2010 |
What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Ki-67 Antigen; Mitotane; Neoplasm Recurr | 2010 |
[Analysis of postoperative recurrence of malignant tumors of adrenal glands].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adult; Antineoplastic Agents, Hormonal; Female; Humans; Male | 2004 |
Clinical features and immunoexpression of p53, MIB-1 and proliferating cell nuclear antigen in adrenal neoplasms.
Topics: Adenoma; Adolescent; Adrenal Gland Neoplasms; Adrenal Glands; Adrenalectomy; Adult; Antineoplastic C | 2005 |
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe | 2006 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang | 2007 |
Adjuvant mitotane in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Child; Child, Pr | 2007 |
Treatment of adrenal carcinomas.
Topics: Adrenal Gland Neoplasms; Adult; Carcinoma; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mi | 1982 |
[Adrenal cortical carcinoma].
Topics: Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adult; Female; Humans; Mitotane; Neoplasm Recurre | 1982 |
Surgical management, DNA content, and patient survival in adrenal cortical carcinoma.
Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Aneuploidy; Carcinoma; Combined Modality | 1995 |
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adult; Aged; Carcinoma; Combined Modality Therapy; Female; Humans; Male; M | 1993 |
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Two years later.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Chemotherapy, Adjuvant; Female; Follow-Up | 1996 |
Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
Topics: Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Carcinoma; Chemotherapy, Adj | 1998 |
[Mitotane treatment in a dog with a recurring adrenocortical carcinoma--a case report].
Topics: Adrenal Cortex Neoplasms; Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cushing Syndrome; Dog | 1999 |
Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Dehydroepiandro | 1999 |
An eleven-year experience with adrenocortical carcinoma.
Topics: Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adult; Carcinoma; Combined Modality Therapy; Fema | 1992 |
A case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications.
Topics: Adrenal Gland Neoplasms; Carcinoma; Carcinosarcoma; Combined Modality Therapy; Female; Humans; Lung | 1992 |
Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1991 |
Radiation therapy for adjunctive treatment of adrenal cortical carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Carcinoma; Child; Combined Modality Therapy; Femal | 1991 |
Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
Topics: Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Carcinoma; Cortisone; Female; Humans; Hydroco | 1990 |
Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane.
Topics: Adrenal Gland Neoplasms; Atrial Natriuretic Factor; Carcinoma; Combined Modality Therapy; Cushing Sy | 1989 |
[Favorable outcome of a recurring malignant adrenocortical tumor under O,P'-DDD therapy].
Topics: Adrenal Cortex Neoplasms; Child, Preschool; Combined Modality Therapy; Humans; Male; Mitotane; Neopl | 1985 |